A.13	Deferiprone – transfusional iron overload – EML and EMLc	
Draft recommendation		⊠ Recommended
		☐ Not recommended
		Justification: Add deferiprone to the list as therapeutic alternative to deferasirox and deferoxamine.
		Commonly available iron chelators including deferoxamine, deferasirox and deferiprone show comparative efficacy profiles. Deferoxamine and deferasirox are already on the EML. Deferiprone is an effective oral iron chelator in reducing cardiac iron and has also been demonstrated to reduce serum ferritin and liver iron with acceptable safety profile. Deferiprone has shown acceptable cost effectiveness profile in most health care setting.
Does the proposed medicine address a relevant public health need?		⊠ Yes
		□No
		☐ Not applicable
		Comments:
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process)		⊠ Yes
		□ No
		☐ Not applicable
		Comments:
Does adequate evidence exist for the safety/harms associated with the proposed medicine?		⊠ Yes
		□ No
(this may be evidence included in the application, and/or additional evidence identified during the review process)		□ Not applicable
		Comments:
identified dan	ing the review process,	
		_
	adverse effects of at may require special	☐ Yes
monitoring?	, , ,	⊠ No
		☐ Not applicable
		Comments:

24^{th} WHO Expert Committee on Selection and Use of Essential Medicines Expert review

Are there any special requirements for the safe, effective and appropriate use of the medicines? (e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)	 Yes No Not applicable Comments: Require monitoring tests e.g serum ferritin level
Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?	☐ Yes ☑ No ☐ Not applicable Comments:
Are there any issues regarding the registration of the medicine by national regulatory authorities? (e.g. accelerated approval, lack of regulatory approval, off-label indication)	☐ Yes ☑ No ☐ Not applicable Comments:
Is the proposed medicine recommended for use in a current WHO guideline? (refer to: https://www.who.int/publications/whoguidelines)	☐ Yes ☑ No ☐ Not applicable Comments: